A meningococcal conjugate vaccine using chemistry developed at Fina Biosolutions has entered a pivotal phase III trial. FinaBio patents for CPIP conjugation were exclusively licensed to the Serum Institute of…
Fina Biosolutions LLC of Rockville, MD has signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine.…
BioTalk summary here. Listen now on Google Play bit.ly/2CzdnA9, iTunes, apple.co/2Arsfze, TuneIn bit.ly/2M60Wmx.
The Johns Hopkins Medical & Surgical Association will present Fina Biosolutions founder and scientific director, Andrew Lees,their “Distinguished Alumni Award”. The award will be presented at theirannual Reunion & Alumni…
For Immediate Release: Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil® Serum Institute of India completes a Phase 3 clinical trial…
Andrew Lees, Fina Biosolutions’ scientific director, speaks on the challenges of purifying conjugate vaccines and vaccine components. Ion Exchange: Pore choices and ion clouds: aspects of resin architecture that affect…
Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving…
Fina Biosolutions licenses CRM197 vaccine component to PATH for use in low-income countries November 15, 2018 06:00 AM Eastern Standard Time ROCKVILLE, Md. - Fina Biosolutions LLC announced today it has reached agreement…
Over the summer, we replaced FinaBio’s ancient ultracold freezers with two new Panasonic freezers from PHC. John Bergen, now the regional manager for PHC, has been trying to sell to…
Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations Rockville, MD., September 27, 2018–Fina Biosolutions announces that the United States…